Published in Hepatology on August 01, 2008
Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol (2010) 1.50
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol (2009) 1.05
IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol (2013) 1.02
Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol (2012) 0.93
Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol (2010) 0.87
Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther (2016) 0.82
Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. J Gastroenterol (2012) 0.79
Engineering biomimetic materials for islet transplantation. Curr Diabetes Rev (2015) 0.77
SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Clin Epidemiol (2014) 0.75
Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol (2016) 0.75
Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 37.89
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
The genome sequence of the malaria mosquito Anopheles gambiae. Science (2002) 20.36
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Comparative genome and proteome analysis of Anopheles gambiae and Drosophila melanogaster. Science (2002) 9.43
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Raxibacumab for the treatment of inhalational anthrax. N Engl J Med (2009) 3.91
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 3.64
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
Plasmodium, human and Anopheles genomics and malaria. Nature (2002) 3.42
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol (2015) 3.01
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Truth survival in clinical research: an evidence-based requiem? Ann Intern Med (2002) 2.87
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol (2011) 2.84
The global impact of vaccination against hepatitis B: a historical overview. Vaccine (2008) 2.84
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology (2010) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology (2010) 2.53
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol (2004) 2.47
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology (2007) 2.43
American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology (2006) 2.39
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (2014) 2.27
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology (2002) 2.21
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol (2010) 2.20
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA (2005) 2.18
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol (2004) 1.92
Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg (2009) 1.91
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood (2002) 1.87
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol (2012) 1.80
Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol (2007) 1.79
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem (2006) 1.78
Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol (2005) 1.77
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
Exploring the psychological effects of deceased organ donation on the families of the organ donors. Clin Transplant (2008) 1.75
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol (2007) 1.65
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62